2016
The Importance of Worsening Heart Failure in Ambulatory Patients Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy
Mallick A, Gandhi PU, Gaggin HK, Ibrahim N, Januzzi JL. The Importance of Worsening Heart Failure in Ambulatory Patients Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy. JACC Heart Failure 2016, 4: 749-755. PMID: 27179830, DOI: 10.1016/j.jchf.2016.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAmbulatory CareAngiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesDisease ProgressionFemaleHeart FailureHospitalizationHumansMaleMiddle AgedMineralocorticoid Receptor AntagonistsNatriuretic Peptide, BrainPatient Care PlanningPeptide FragmentsProportional Hazards ModelsSodium Potassium Chloride Symporter InhibitorsStandard of CareTreatment OutcomeConceptsHeart failureChronic HFrEFNT-proBNPEjection fractionN-terminal pro-B-type natriuretic peptide concentrationsHigher loop diuretic dosesAngiotensin-converting enzyme inhibitorB-type natriuretic peptideAmbulatory heart failureAmino-Terminal ProJugular venous distensionLoop diuretic dosesAcute heart failureDecompensated heart failureReduced ejection fractionEvent-free survivalNatriuretic peptide concentrationsHigher ejection fractionStandard of careRelevant clinical eventsDiuretic therapyHF managementCardiovascular deathDiuretic dosesVenous distension
2015
Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction
Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, Fiuzat M, Rocca H, Januzzi JL. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American Heart Journal 2015, 169: 404-411.e3. PMID: 25728731, DOI: 10.1016/j.ahj.2014.12.012.Peer-Reviewed Original ResearchConceptsElevated galectin-3Mineralocorticoid receptor antagonistsCV event ratesMRA therapyGalectin-3 concentrationsQuality of lifeGalectin-3CV eventsHeart failureMRA useLeft ventricular systolic dysfunctionMineralocorticoid receptor antagonist useTreatment-related adverse eventsEvent ratesBaseline galectin-3Ventricular remodeling indexChronic heart failureOutcomes of patientsReduced ejection fractionVentricular systolic dysfunctionReceptor antagonist useSignificant renal dysfunctionFirst CV eventHeart failure biomarkersChronic HFrEF